The aim of the present study was to determine the effect of the acetylcholinesterase inhibitor rivastigmine on gait in 21 newly diagnosed patients with mild to moderate Alzheimer’s disease. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.